Psilocybin eased depression but not BPD symptoms in a nine-person pilot
The open-label pilot tested a specific worry in psychedelic research — that borderline personality disorder blunts response to psilocybin for depression. In this small sample, it didn't.
Borderline personality disorder (BPD) frequently co-occurs with major depressive disorder (MDD), and some prior literature has suggested that comorbidity may blunt how well depression responds to treatment generally. Because people with BPD have typically been excluded from psilocybin depression trials, whether that pattern holds for psychedelic treatment specifically has gone untested — until a pilot study published this month in Clinical Neuropharmacology [s1].
The design
Adults aged 18 to 65 with a DSM-5 diagnosis of both MDD and BPD were enrolled in an open-label pilot study of a single dose of psilocybin [s1]. Assessments were conducted one week before dosing (baseline), on the dosing day, and at 1, 2, and 4 weeks after [s1]. The co-primary outcomes were change in depressive symptoms and change in BPD symptoms from baseline to the study's endpoint, analyzed with paired-samples t tests [s1]. Nine participants were enrolled — four male, mean age 31.3 years [s1].
What it found
MDD symptoms changed significantly from baseline to the final visit: from a mean score of 28.56 (SD 4.53) at baseline to 17.22 (SD 10.39) at the final visit, a statistically significant reduction (t(8) = −4.217, p = 0.003, Cohen's d = 1.41 — a large effect size by conventional statistical standards) [s1]. BPD symptom scores, by contrast, did not change significantly from baseline to the study's endpoint [s1].
What the split result suggests
The finding that depression improved while BPD symptoms didn't is itself the study's central and most useful result, because it speaks directly to the concern that motivated the trial: whether comorbid BPD would interfere with psilocybin's effect on depression. In this small sample, it didn't — depressive symptoms improved with a fairly large effect size, even though the participants all also had BPD [s1]. The authors' own framing is cautious but specific: the results "suggest that BPD does not appear to interfere with response to depressive symptoms" [s1], while stopping well short of claiming psilocybin treats BPD symptoms themselves, which the trial's own primary data on that measure doesn't support.
What this doesn't establish
Nine participants is a very small sample, and this was an open-label study — everyone knew they were receiving psilocybin, with no placebo control and no blinding, which is a substantial limitation for a self-reported symptom measure like depression severity, where expectation effects can be considerable. The lack of a placebo arm makes it impossible to separate a genuine psilocybin-specific effect from the general benefit patients might experience from participating in a supportive clinical trial, from natural symptom fluctuation over the study's four-week window, or from the psychological support that typically accompanies dosing sessions. People with BPD were specifically excluded from most prior psilocybin depression trials in part due to safety and risk-management concerns — including risks around impulsivity, dissociation, and emotional dysregulation that can characterize BPD — and this trial doesn't report the detail needed to assess how those specific risks played out, or didn't, in this small group.
What this adds, carefully
This is a hypothesis-generating pilot study, exactly the kind of small, safety-oriented trial meant to inform whether a larger, controlled study is worth running — not a study designed or powered to establish efficacy on its own. Its main contribution is descriptive: a specific population previously excluded from psilocybin depression research was included here, and depression improved in a way roughly consistent with what's been reported in psilocybin trials for depression without BPD comorbidity, while BPD symptoms specifically did not change.
What to watch
Whether a larger, randomized, placebo-controlled trial in this same population — MDD with comorbid BPD — is conducted to confirm these preliminary findings and better characterize safety. Psilocybin is not approved for MDD, BPD, or any indication; this article describes a small pilot trial and is not medical advice.
Sources
- An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder — Clinical Neuropharmacology, 13 April 2026
Sources
- An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder — Clinical Neuropharmacology , April 13, 2026
More on
Psilocybin eased depression within two days, but the placebo gap closed by one year
In 35 patients with recurrent major depression, psilocybin beat an active placebo through day 42. On self-reported measures the effect lingered further, but the trial's primary endpoint showed no difference at 365 days.
One psilocybin dose eased chronic suicidal ideation for 12 weeks, in 20 patients
By the study's end, 70% had scores low enough to be considered near-resolution. There was no placebo arm — every participant knew what they'd received.
The receptor psychedelics target is less abundant in depression, imaging review finds
Pooling 31 studies of 556 patients, cortical 5-HT2A binding was lower in unmedicated depression than in controls. The post-mortem studies mostly found nothing, and the tracers used shape the result.
Clozapine outperformed other antipsychotics across six diagnoses — but not in BPD
A within-individual analysis of 505,474 people in Finland and Sweden found lower psychiatric hospitalisation on clozapine in every disorder studied except borderline personality disorder, with no excess mortality signal.